China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
86 hedge funds and large institutions have $1.74B invested in China Biologic Products Holdings, Inc. in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 27 increasing their positions, 34 reducing their positions, and 14 closing their positions.
2,734% more call options, than puts
Call options by funds: $12.8M | Put options by funds: $450K
1.27% more ownership
Funds ownership: 36.62% → 37.88% (+1.3%)
4% more capital invested
Capital invested by funds: $1.68B → $1.74B (+$62.3M)
3% less funds holding
Funds holding: 89 → 86 (-3)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
21% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 34
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Athos Capital
Hong Kong
|
+$67.1M |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$64.8M |
| 3 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$49.3M |
| 4 |
DKCM
Davidson Kempner Capital Management
New York
|
+$29.8M |
| 5 |
Millennium Management
New York
|
+$27.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$74M |
| 2 |
Capstone Investment Advisors
New York
|
-$50.2M |
| 3 |
YCMGA
York Capital Management Global Advisors
New York
|
-$35.7M |
| 4 |
PAM
PSquared Asset Management
Zurich,
Switzerland
|
-$24.2M |
| 5 |
Two Sigma Investments
New York
|
-$22.2M |
CBPO Hedge Fund Activity: Q1 2021 in Review
86 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q1 2021, worth a combined $1.74B — up 3.7% from $1.68B a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CBPO and 11 opened new positions — a net loss of 3 holders — while 34 trimmed existing stakes and 27 added.
The largest buyer was Athos Capital, adding an estimated $67.1M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $74M sold.
- 86 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q1 2021, down from 89 in Q4 2020.
- Funds reported $1.74B of China Biologic Products Holdings, Inc. stock for Q1 2021, up 3.7% quarter-over-quarter.
- 11 funds opened new China Biologic Products Holdings, Inc. positions in Q1 2021 and 14 closed out, a net change of -3 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q1 2021 was Athos Capital, an estimated $67.1M added.
- The largest China Biologic Products Holdings, Inc. seller in Q1 2021 was Renaissance Technologies, an estimated $74M sold.
Based on aggregated 13F filings for Q1 2021.